BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 221 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.69 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,166,133 | -30.3% | 305,951 | -30.7% | 0.00% | 0.0% |
| Q2 2023 | $3,109,103 | -13.8% | 441,634 | +2.1% | 0.00% | 0.0% |
| Q1 2023 | $3,608,551 | -51.4% | 432,680 | -33.0% | 0.00% | -66.7% |
| Q4 2022 | $7,418,698 | +185.3% | 646,228 | +213.2% | 0.00% | +200.0% |
| Q3 2022 | $2,600,000 | +61.3% | 206,334 | +35.4% | 0.00% | 0.0% |
| Q2 2022 | $1,612,000 | -30.8% | 152,438 | +6.5% | 0.00% | 0.0% |
| Q1 2022 | $2,328,000 | -68.4% | 143,148 | -73.1% | 0.00% | -50.0% |
| Q4 2021 | $7,377,000 | +51.7% | 532,650 | +57.4% | 0.00% | 0.0% |
| Q3 2021 | $4,863,000 | +71.8% | 338,388 | +89.0% | 0.00% | +100.0% |
| Q2 2021 | $2,831,000 | +47.0% | 179,019 | -5.5% | 0.00% | 0.0% |
| Q1 2021 | $1,926,000 | -51.0% | 189,416 | -64.1% | 0.00% | 0.0% |
| Q4 2020 | $3,933,000 | -20.3% | 527,873 | -63.3% | 0.00% | -50.0% |
| Q3 2020 | $4,936,000 | +552.0% | 1,437,055 | +804.5% | 0.00% | – |
| Q2 2020 | $757,000 | -92.6% | 158,876 | -96.9% | 0.00% | -100.0% |
| Q1 2020 | $10,166,000 | -46.3% | 5,083,238 | -7.4% | 0.01% | -28.6% |
| Q4 2019 | $18,935,000 | +117.6% | 5,488,287 | +80.7% | 0.01% | +133.3% |
| Q3 2019 | $8,703,000 | +4.2% | 3,037,809 | +37.9% | 0.00% | 0.0% |
| Q2 2019 | $8,349,000 | +100.7% | 2,202,794 | +331.0% | 0.00% | +50.0% |
| Q1 2019 | $4,160,000 | +310.7% | 511,113 | +307.1% | 0.00% | – |
| Q4 2018 | $1,013,000 | +18.6% | 125,544 | +12.2% | 0.00% | – |
| Q3 2018 | $854,000 | +135.9% | 111,885 | +76.9% | 0.00% | – |
| Q2 2018 | $362,000 | -74.0% | 63,239 | -78.3% | 0.00% | -100.0% |
| Q1 2018 | $1,390,000 | +181.9% | 291,379 | +190.7% | 0.00% | – |
| Q4 2017 | $493,000 | -17.6% | 100,222 | -12.2% | 0.00% | – |
| Q3 2017 | $598,000 | +69.4% | 114,114 | +79.8% | 0.00% | – |
| Q2 2017 | $353,000 | -41.7% | 63,479 | -11.9% | 0.00% | – |
| Q1 2017 | $605,000 | -4.3% | 72,041 | -27.8% | 0.00% | – |
| Q4 2016 | $632,000 | +62.5% | 99,803 | +13.1% | 0.00% | – |
| Q3 2016 | $389,000 | +62.8% | 88,256 | +4.9% | 0.00% | – |
| Q2 2016 | $239,000 | +16.0% | 84,170 | +15.6% | 0.00% | – |
| Q1 2016 | $206,000 | -86.3% | 72,835 | -50.0% | 0.00% | -100.0% |
| Q4 2015 | $1,502,000 | +72.1% | 145,603 | +90.2% | 0.00% | 0.0% |
| Q3 2015 | $873,000 | -20.9% | 76,535 | +3.6% | 0.00% | 0.0% |
| Q2 2015 | $1,103,000 | +64.9% | 73,884 | -0.3% | 0.00% | – |
| Q1 2015 | $669,000 | -27.1% | 74,084 | -1.8% | 0.00% | -100.0% |
| Q4 2014 | $918,000 | – | 75,474 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Burrage Capital Management LLC | 864,916 | $13,674,000 | 13.71% |
| Sarissa Capital Management LP | 4,261,000 | $67,366,000 | 5.36% |
| ORACLE INVESTMENT MANAGEMENT INC | 1,920,733 | $30,367,000 | 4.18% |
| HealthCor Management, L.P. | 3,248,100 | $51,352,000 | 2.05% |
| Parkman Healthcare Partners LLC | 351,961 | $5,565,000 | 1.22% |
| Bain Capital Public Equity Management II, LLC | 1,560,730 | $24,675,000 | 1.06% |
| Baker Brothers Advisors | 12,710,818 | $200,958,000 | 0.88% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,835,000 | $44,821,000 | 0.80% |
| Biondo Investment Advisors, LLC | 265,840 | $4,203,000 | 0.72% |
| EAM Global Investors LLC | 157,065 | $2,483,000 | 0.69% |